Akcea Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The only pricing detail listed in the filing was that the offering is valued up to $100 million, although this number is usually just a placeholder. The company intends to list its stock on the Nasdaq under the symbol AKCA.
The underwriters for the offering are Cowen, Stifel and Wells Fargo.
This is a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The firm’s main goal is to become the premier company offering treatments for inadequately treated lipid disorders.
Akcea is advancing a mature pipeline of four novel drugs with the potential to treat multiple diseases. Its drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy (FPL).
FCS and FPL are both severe, rare, genetically defined lipid disorders characterized by extremely elevated levels of triglycerides. Both diseases have life-threatening consequences and the lives of patients with these diseases are impacted daily by the associated symptoms. In its clinical program, Akcea has observed consistent and substantial (>70%) decreases in triglycerides and improvements in other manifestations of FCS, including pancreatitis attacks and abdominal pain. Management believes the safety and efficacy data from the volanesorsen program demonstrate a favorable risk-benefit profile for patients with FCS. In the third quarter of 2017, Akcea plans to file for marketing authorization for volanesorsen to treat patients with FCS.
The company intends to use the net proceeds from this offering to further develop its pipeline, with the remainder going toward working capital and general corporate purposes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
